Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
36 Results for "
FOXO3
" in MedChemExpress (MCE) Product Catalog:
Products (36)
36 Results for "FOXO3" in MCE Product Catalog:
Cat. No.: HY-P80677A
Synonyms: FOXO3; FKHRL1; FOXO3A; Forkhead box protein O3; AF6q21 protein; Forkhead in rhabdomyosarcoma-like 1
Cat. No.: HY-P701170
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: FOXO3; Forkhead, Drosophila, Homolog Of, In Rhabdomyosarcoma-Like 1; Prev. FKHRL1; Forkhead Box O3A; Prev. FOXO3A; AF6q21 Protein; AF6q21; FOXO3A-Short; FOXO2; FKHRL1P2; Forkhead In Rhabdomyosarcoma-Like 1; FOXO3A-; Forkhead Box Protein O3; Forkhead Box O
Species:
Human
Source:
HEK293
Cat. No.: HY-162050
Target:
Research Areas:
8AQ?Cu?5Iu is an activator of SIRT1. 8AQ?Cu?5Iu exhibits neuroprotective effects by
modulating the SIRT1/3-FOXO3a signaling pathway. 8AQ?Cu?5Iu can used in study attenuating neurodegenerative diseases .
Cat. No.: HY-122894
CAS No.: 2589088-07-1
Target:
Research Areas:
Ch-319 is a Triphenyltin (IV) carboxylate derivative. Ch-319 reduces androgen receptor expression, AKT and PRAS40 phosphorylation levels, and increases FOXO3a expression. Ch-319 increases Apoptosis. Ch-319 can be used in the research of prostate cancer .
Cat. No.: HY-15186C
CAS No.: 1491138-24-9
Synonyms: GDC-0068 tosylate; RG7440 tosylate
Ipatasertib (GDC-0068) tosylate is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib tosylate synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib tosylate also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness .
Cat. No.: HY-116604A
CAS No.: 21314-60-3
Synonyms: PD 139530 hydrochloride
RLX (PD 139530) hydrochloride is the hydrochloride of RLX (HY-116604). RLX is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness .
Cat. No.: HY-182469
Target:
Lactate Dehydrogenase AMPK FOXO Interleukin Related Reactive Oxygen Species (ROS) TNF Receptor Bcl-2 Family Caspase Apoptosis
Research Areas:
FuBIG is an iminoguanidine derivative with neuroprotective effects. FuBIGL inhibits L-LDH activation and reduces lactate production. FuBIGL exerts protective effects on inflammatory nerve cells, upregulates the expressions of AMPK, pAMPK and FOXO3, and activates the AMPK pathway in cells. FuBIG exerts anti-inflammatory effects by reducing pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and increasing the anti-inflammatory cytokine IL-10. FuBIG maintains mitochondrial membrane potential, alleviates mitochondrial dysfunction, reduces ROS production, and relieves oxidative stress. FuBIG upregulates Bcl-2, downregulates Bax and Caspase-3, and inhibits cell apoptosis (apoptosis). FuBIG improves metabolic disorders in diabetic mice, decreases the levels of LDL-C, ALT and AST, and increases HDL-C level simultaneously. FuBIG can be used in the research of diabetic neuroinflammation .
Cat. No.: HY-15186R
CAS No.: 1001264-89-6
Synonyms: GDC-0068 (Standard); RG7440 (Standard)
Target:
Research Areas:
Ipatasertib (Standard) is the analytical standard of Ipatasertib (HY-15186). This product is intended for research and analytical applications. Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .
Cat. No.: HY-119884
CAS No.: 1261080-40-3
DC-120 is an ATP-competitive AKT inhibitor, with particular activity against AKT1 (an IC50 of 0.153 μM). DC-120 functionally blocks AKT kinase activity and reduces the phosphorylation levels of FOXO3a and GSK-3β. DC-120 induces cancer cell apoptosis (apoptosis) and inhibits cancer cell proliferation. DC-120 activates the mTORC1 pathway via the Ca 2+/calmodulin (calmodulin)/hVps34 signaling pathway. DC-120 abrogates AKT-mediated inhibition of CRAF, thereby activating the MEK/ERK MAPK pathway. DC-120 exerts anti-tumor activity in a nude mouse hepatocellular carcinoma xenograft model. DC-120 can be used for hepatocellular carcinoma-related research .
Cat. No.: HY-183402
CAS No.: 917813-60-6
Synonyms: GO-Y026
Target:
Research Areas:
FLLL12 (GO-Y026) is a curcumin analog anticancer agent. FLLL12 inhibits the phosphorylation of AKT, Bcl-2, Bid, EGFR, mTOR, FOXO1a, FOXO3a, STAT3, HER2/neu, as well as pancreatic AKT/STAT3; upregulates the expression of Bim and DR5; and activates PTPs. FLLL12 regulates downstream pathways, induces mitochondria-mediated and DR5-dependent extrinsic apoptosis, inhibits cancer cell viability, proliferation, anchorage-independent growth and migration, and exerts a synergistic effect with Doxorubicin (HY-15142A). FLLL12 can be used in research related to head and neck squamous cell carcinoma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, colon cancer and colorectal cancer [3] .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
